Información del artículo
Abstract
Autoimmune bullous diseases are relatively uncommon and their treatment—although generally similar—may vary depending on the dermatologist. Within this group of diseases, the most common are pemphigus vulgaris and pemphigus foliaceus, bullous and mucosal pemphigoid, linear immunoglobulin A disease, and dermatitis herpetiformis. In recent years, the therapeutic arsenal has been extended by new drugs, some of which have changed the prognosis of these diseases. This article describes current management protocols for these processes as indicated in the literature and derived from the experience of specialized clinics for bullous diseases. We also present the findings from an Internet survey on therapeutic approaches in pemphigus vulgaris answered by more than 40 dermatologists who work primarily in Spanish hospital clinics.
Key words:
treatment
pemphigus
pemphigoid
dermatitis herpetiformis
linear immunoglobulin A
Resumen
Las enfermedades ampollosas autoinmunes constituyen un grupo de entidades relativamente infrecuentes cuyo tratamiento, aunque semejante, varía en función de las escuelas dermatológicas. Dentro de este grupo las más frecuentes son el pénfigo vulgar y foliáceo, el penfigoide ampolloso y de mucosas, la enfermedad IgA lineal y la dermatitis herpetiforme.
En los últimos años se han incluido en el arsenal terapéutico fármacos que han cambiado en ocasiones el pronóstico de las mismas.
Recogemos en este artículo los protocolos de actuación actuales en estos procesos basados en la literatura y en la experiencia de consultas monográficas de enfermedades ampollosas. Así mismo, hemos recogido los datos de una encuesta vía internet sobre los métodos terapéuticos en pénfigo vulgar de más de 40 dermatólogos con experiencia habitualmente hospitalaria en España.
Palabras clave:
tratamiento
pénfigo
penfigoide
dermatitis herpetiforme
IgA lineal
El Texto completo está disponible en PDF
References
[2.]
R. Rivera, F. Vanaclocha, L. Iglesias.
Tratamiento del pénfigo.
Piel, 20 (2005), pp. 95-102
[3.]
J.C. Bystryn, J. Rudolph.
Pemphigus.
Lancet, 366 (2005), pp. 61-73
[4.]
V. Mahajan, N. Sharma, R. Chander, G. Garg.
Twelve year clinico-therapeutic experience in pemphigus: retrospective study of 54 cases.
Int J Dermatol, 44 (2005), pp. 821-827
[5.]
C. Chams-Davatchi, N. Esmaili, M. Danespazhooh, M. Valikhani, K. Balighi, Z. Hallaji, et al.
Randomized controlled open label trial of four treatment regimens for pemphigus vulgaris.
J Am Acad Dermatol, 57 (2007), pp. 622-628
[6.]
M. Pfütze, A. Niedermeier, M. Hertl, R. Eming.
Introducing a novel autoimmune bullous skin disorder intensity score in pemphigus.
Eur J Dermatol, 17 (2007), pp. 4-11
[7.]
S. Ikeda, S. Imamura, I. Hashimoto, S. Morioka, M. Sakuma, H. Ogawa.
History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan.
Arch Dermatol Res, 295 (2003), pp. s12-s16
[8.]
G.C. Toth, M.F. Jonkman.
Therapy of pemphigus.
Dermatol Clin, 19 (2001), pp. 761-767
[9.]
J. Gisbert, F. Gomollon, C. Cara, M. Luna, Y. González, J. Pajares, et al.
Thiopurine methyltransferase activity in Spain. 14.545 patients.
Dig Dis Sci, 52 (2007), pp. 1262-1269
[10.]
W. Aberer, E. Wolff, G. Stingl.
Azathioprine in the treatment of pemphigus vulgaris.
J Am Acad Dermatol, 16 (1987), pp. 527-533
[11.]
C. Chams, R. Nonadal, M. Daneshpazooh, M. Valikhano, B. Hallaji, M. Burzegar, et al.
Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris.
Ann Dermatol Venereol, 129 (2002), pp. 23-25
[12.]
A.H. Enk, J. Knop.
Treatment of pemphigus vulgaris with mycophenolate mofetil.
Lancet, 349 (1997), pp. 541
[13.]
A. Powell, S. Albert, S. AlFares, K. Karman, J. Setterfield, B. Bhogal, et al.
An evaluation of the usefulness of mycophenolate mofetil in pemphigus.
Br J Dermatol, 149 (2003), pp. 138-145
[14.]
D. DeHoratius, B. Sperber, V. Werth.
Glucocorticoids in the treatment of bullous diseases.
Dermatol Ther, 15 (2002), pp. 298-310
[15.]
K.E. Harman, S. Albert, M.M. Black.
Guidelines for the management of pemphigus vulgaris.
Br J Dermatol, 149 (2003), pp. 926-937
[16.]
L. Fox, A.G. Pandye.
Pulse intravenous cyclophosphamide therapy for dermatologic diseases.
Dermatol Clin, 18 (2000), pp. 459-473
[17.]
D. Cummins, D. Mimouni, G. Anhalt, C. Nousari.
Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus.
J Am Acad Dermatol, 49 (2003), pp. 276-280
[18.]
L. Engineer, K.C. Bhol, A.R. Ahmed.
Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
J Am Acad Dermatol, 43 (2000), pp. 1049-1057
[19.]
J.C. Bystryn, B. Jiao, B. Natous.
Treatment of pemphigus with intravenous immunoglobulins.
J Am Acad Dermatol, 47 (2002), pp. 358-363
[20.]
R. Ahmed, M. Dahl.
Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases.
Arch Dermatol, 139 (2003), pp. 1051-1059
[21.]
S. Segura, P. Iranzo, I. Martínez, J.M. Mascaró, M. Alsina, J. Herrero, et al.
High dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: 19 cases.
J Am Acad Dermatol, 56 (2007), pp. 960-967
[22.]
S. Jolles, A.C. Sewell, S.A. Misbah.
Clinical uses of intravenous immunoglobulins.
Clin Exp Immun, 142 (2005), pp. 1-11
[23.]
J.C. Bystryn, J. Rudolph.
IvIG treatment of pemphigus. How it works and how to use it.
J Invest Dermatol, 125 (2005), pp. 1093-1098
[24.]
S.W. Yeh, N. Sami, R.A. Ahmed.
Treatment of pemphigus: current and emerging options.
Am J Clin Dermatol, 6 (2005), pp. 327-342
[25.]
V. Pont, J.C. Sánchez Carazo, V. Oliver.
Plasmaféresis en Dermatología.
Piel, 14 (1999), pp. 323-327
[26.]
M.S. Turner, D. Sutton, D.N. Saunder.
The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris.
J Am Acad Dermatol, 43 (2000), pp. 1058-1063
[27.]
A. España, M. Fernández, P. Lloret, A. Sánchez Ibarrola, C. Panizo.
Long term complete remission of severe pemphigus vulgaris with anti CD20 antibody therapy and immunophenotype correlations.
J Am Acad Dermatol, 50 (2004), pp. 974-976
[28.]
I. Domínguez, S. Pérez, R. Goiriz, J. Sánchez, J. Fernández Herrera.
Pénfigo vulgar tratado con rituximab.
Actas Dermosifiliogr, 97 (2006), pp. 221-222
[29.]
R. Ahmed, Z. Spigelman, L. Cavacini, M. Posner.
Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
N Engl J Med, 355 (2006), pp. 1772-1779
[30.]
M.S. Goh, C. McCormack, H.V. Dinh, B. Welsh, P. Foley, H.M. Prince.
Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open label pilot study in five patients.
Br J Dermatol, 156 (2007), pp. 990-996
[31.]
E. Schmidt, C.S. Seitz, S. Benoit, E.B. Bröker, M. Goebeler.
Rituximab in autoimmune bullous diseases: mixed responses and adverse effects.
Br J Dermatol, 156 (2006), pp. 353-356
[32.]
D. Mimouni, C. Nousari, D. Cummins, D. Kouba, M. David, G. Anhalt.
Differences and similarities among expert opinión on the diagnosis and treatment of pemphigus vulgaris.
J Am Acad Dermatol, 49 (2003), pp. 1059-1062
[33.]
J.C. Bystryn.
How should pemphigus be treated.
J Eur Acad Dermatol, 16 (2002), pp. 562-563
[34.]
D. Ioannides, E. Chrysomellis, J.C. Bystryn.
Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus.
Arch Dermatol, 136 (2000), pp. 868-872
[35.]
M. Olszewska, Z. Kolacinska, J. Sulej, H. labecka, J. Cwikla, U. Natorska, et al.
Efficacy and safety of cyclophosphamide and cyclosporine as adjuvant drugs in pemphigus vulgaris.
Am J Clin Dermatol, 8 (2007), pp. 85-92
[36.]
P. Joly, H. Mouquet, J.C. Roujeau, M. Incan, D. Gilbert, S. Jacquot, et al.
A single cycle of rituximab for the treatment of severe pemphigus.
N Engl J Med, 357 (2007), pp. 542-552
[37.]
K.B. Yancey, C.A. Egan.
Pemphigoid: clinical, histologic, immuno-pathologic, and therapeutic considerations.
JAMA, 284 (2000), pp. 350-356
[38.]
H.C. Nousari, G.J. Anhalt.
Pemphigus and bullous pemphigoid.
Lancet, 354 (1999), pp. 667-672
[40.]
K.B. Yancey.
The pathophysiology of autoimmune blistering diseases.
J Clin Invest, 115 (2005), pp. 825-828
[41.]
L. Vaillant, P. Bernard, P. Joly, C. Prost, B. Labeille, C. Bedane, et al.
Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group.
Arch Dermatol, 134 (1998), pp. 1075-1080
[42.]
W. Westerhof.
Treatment of bullous pemphigoid with topical clobetasol propionate.
J Am Acad Dermatol, 20 (1989), pp. 458-461
[43.]
P. Joly, J.C. Roujeau, J. Benichou, C. Picard, B. Dreno, E. Delaporte, et al.
A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.
N Engl J Med, 346 (2002), pp. 321-327
[44.]
D.P. Fivenson, D.L. Breneman, G.B. Rosen, C.S. Hersh, S. Cardone, D. Mutasim.
Nicotinamide and tetracycline therapy of bullous pemphigoid.
Arch Dermatol, 130 (1994), pp. 753-758
[46.]
R.E. Jenkins, S. Hern, M.M. Black.
Clinical features and management of 87 patients with pemphigoid gestationis.
Clin Exp Dermatol, 24 (1999), pp. 255-259
[47.]
J.M. Mascaró Jr, M. Lecha, J.M. Mascaró.
Fetal morbidity in herpes gestationis.
Arch Dermatol, 131 (1995), pp. 1209-1210
[48.]
A. España, J. del Olmo, M. Marquina, S. Fernández, C. Panizo, M. Maldonado.
Penfigoide de mucosas: manifestaciones clínicas y tratamiento con corticoides, dapsona y ciclofosfamida en cinco pacientes.
Actas Dermosifiliogr, 96 (2005), pp. 357-364
[49.]
T.E. Fleming, N.J. Korman.
Cicatricial pemphigoid.
J Am Acad Dermatol, 43 (2000), pp. 571-591
[50.]
M.E. Eschle-Meniconi, S.R. Ahmed, C.S. Foster.
Mucous membrane pemphigoid: an update.
Curr Opin Ophthalmol, 16 (2005), pp. 303-307
[51.]
D.F. Mutasim, N.J. Pelc, G.J. Anhalt.
Cicatricial pemphigoid.
Dermatol Clin, 11 (1993), pp. 499-510
[52.]
J. Alonso-Llamazares, L.E. Gibson, R.S. Rogers 3rd.
Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience.
Int J Dermatol, 46 (2007), pp. 910-919
[54.]
A.S. Oxentenko, J.A. Murray.
Celiac disease and dermatitis herpetiformis: the spectrum of gluten-sensitive enteropathy.
Int J Dermatol, 42 (2003), pp. 585-587
[55.]
J.J. Zone, L.J. Meyer, M.J. Petersen.
Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis.
Arch Dermatol, 132 (1996), pp. 912-918
[56.]
W. Dieterich, T. Ehnis, M. Bauer, P. Donner, U. Volta, E.O. Riecken, et al.
Identification of tissue transglutaminase as the autoantigen of celiac disease.
Nat Med, 3 (1997), pp. 797-801
[57.]
M. Sardy, S. Karpati, B. Merkl, M. Paulsson, N. Smyth.
Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis.
J Exp Med, 195 (2002), pp. 747-757
[58.]
V. Kumar, H. Zane, N. Kaul.
Serologic markers of glutensensitive enteropathy in bullous diseases.
Arch Dermatol, 128 (1992), pp. 1474-1478
[59.]
V. Kumar, E. Hemedinger, T.P. Chorzelski, E.H. Beutner, J.E. Valeski, C. Kowalewski.
Reticulin and endomysial antibodies in bullous diseases. Comparison of specificity and sensitivity.
Arch Dermatol, 123 (1987), pp. 1179-1182
[60.]
D. Villalta, M.G. Alessio, M. Tampoia, E. Tonutti, I. Brusca, M. Bagnasco, et al.
Diagnostic accuracy of IgA anti-tissue transglutaminase antibody assays in celiac disease patients with selective IgA deficiency.
Ann N Y Acad Sci, 1109 (2007), pp. 212-220
[61.]
D. Villalta, M.G. Alessio, M. Tampoia, E. Tonutti, I. Brusca, M. Bagnasco, et al.
Testing for IgG class antibodies in celiac disease patients with selective IgA deficiency. A comparison of the diagnostic accuracy of 9 IgG anti-tissue transglutaminase, 1 IgG anti-gliadin and 1 IgG anti-deaminated gliadin peptide antibody assays.
Clin Chim Acta, 382 (2007), pp. 95-99
[62.]
B. Sigurgeirsson, B.A. Agnarsson, B. Lindelof.
Risk of lymphoma in patients with dermatitis herpetiformis.
BMJ, 308 (1994), pp. 13-15
[63.]
P. Collin, E. Pukkala, T. Reunala.
Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease.
Gut, 38 (1996), pp. 528-530
[64.]
A.J. Swerdlow, S. Whittaker, L.M. Carpenter, J.S. English.
Mortality and cancer incidence in patients with dermatitis herpetiformis: a cohort study.
Br J Dermatol, 129 (1993), pp. 140-144
[65.]
J.J. Garioch, H.M. Lewis, S.A. Sargent, J.N. Leonard, L. Fry.
25 years’ experience of a gluten-free diet in the treatment of dermatitis herpetiformis.
Br J Dermatol, 131 (1994), pp. 541-545
[66.]
M.T. Bardella, C. Fredella, C. Trovato, E. Ermacora, R. Cavalli, V. Saladino, et al.
Long-term remission in patients with dermatitis herpetiformis on a normal diet.
Br J Dermatol, 149 (2003), pp. 968-971
Copyright © 2008. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
